Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia.
about
Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparumMalaria in the Greater Mekong Subregion: heterogeneity and complexityIn vitro and in vivo assessment of the anti-malarial activity of Caesalpinia pluviosaEmergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal studyMaking the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugsDiscovery of a Plasmodium falciparum glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase inhibitor (R,Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide (ML276) that reducesArtesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trialIn vitro sensitivity of Plasmodium falciparum from China-Myanmar border area to major ACT drugs and polymorphisms in potential target genesCurrent status of artemisinin-resistant falciparum malaria in South Asia: a randomized controlled artesunate monotherapy trial in BangladeshImproving pharmacokinetic-pharmacodynamic modeling to investigate anti-infective chemotherapy with application to the current generation of antimalarial drugsEfficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trialImplications of Glutathione Levels in the Plasmodium berghei Response to Chloroquine and ArtemisininThe Effects of Transdermally Delivered Oleanolic Acid on Malaria Parasites and Blood Glucose Homeostasis in P. berghei-Infected Male Sprague-Dawley RatsMonitoring parasite diversity for malaria elimination in sub-Saharan AfricaBioinformatics and Drug Discovery.Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria.Hemoglobin E and Glucose-6-Phosphate Dehydrogenase Deficiency and Plasmodium falciparum Malaria in the Chittagong Hill Districts of Bangladesh.Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis.Therapeutic efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in a high-transmission area in northwest EthiopiaThe clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread.Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy changePlasmodium falciparum gametocyte carriage is associated with subsequent Plasmodium vivax relapse after treatment.Performance of the CareStart™ G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screeningEx vivo activity of endoperoxide antimalarials, including artemisone and arterolane, against multidrug-resistant Plasmodium falciparum isolates from Cambodia.Emerging artemisinin resistance in the border areas of Thailand.Efficacy of intravenous methylene blue, intravenous artesunate, and their combination in preclinical models of malaria.A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old Nigerian children.Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children.Malaria biology and disease pathogenesis: insights for new treatments.Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in central VietnamGenetic diversity and lack of artemisinin selection signature on the Plasmodium falciparum ATP6 in the Greater Mekong Subregion.Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challengesTherapeutic efficacies of artemisinin-based combination therapies in Nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments.Quantum dots: a new tool for anti-malarial drug assays.Assessment of molecular markers for anti-malarial drug resistance after the introduction and scale-up of malaria control interventions in western Kenya.Artemether-lumefantrine compared to atovaquone-proguanil as a treatment for uncomplicated Plasmodium falciparum malaria in travelers.Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Enfranze, north-west EthiopiaStandardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimatorPK4, a eukaryotic initiation factor 2α(eIF2α) kinase, is essential for the development of the erythrocytic cycle of Plasmodium.
P2860
Q21032477-B590A07B-B76F-4473-A64D-81756D29557EQ21032492-D66BD8F7-6AAF-477C-9B7D-F1AB59748717Q21034096-74B51A3C-0294-4209-B21E-EB0762C1A9BCQ24598695-5228B276-A088-4E43-922E-21DFECF4511AQ27025529-3123A849-1286-4FC9-9186-F12F016ECADFQ28271436-C9869A71-8BFA-447D-9947-2E6763F14C5FQ28478138-03913C28-1016-4F82-894A-A6F0378DC9C9Q28484068-499EDB47-0711-4C91-9D3D-2B92C94161D9Q28484416-07518C3C-441E-45E9-8EE4-6FF25D160F10Q28534701-B6E5624C-FF4E-4A55-8572-4884AF32EDABQ28541521-FF27F1DE-C9C4-4937-B5C1-42532727D54CQ28547488-BB44C7DB-B907-498A-88CE-AB57E052EDD9Q28554747-D635A301-3242-4C3A-A18E-3163A497285AQ28610494-C6580BF1-22F7-467A-8226-D1DED65DCDE9Q30395256-B61152F5-4791-492C-BCA1-55354EFAB50FQ30867699-4A67C589-4D07-4A03-AB59-AD814F597ECFQ30976084-EEC7C4FC-AE17-4BA7-9465-E23A7A52C04CQ30995133-37450D75-A78E-4CF3-A93F-BFA37521C13DQ33605847-81674993-B48A-4203-ACB5-596A07613B44Q33655603-3BA7CCDC-BEC9-43E9-AB34-48C53CB24AE5Q33726272-AC209101-184C-4F07-8C10-40B11DD56276Q33886228-34D5A8FE-A0D4-49F3-B9BE-2FB50CA427DFQ34099217-AF80D2E6-E434-48C1-BAFB-3E9322AB19DAQ34298916-6FCEDE1A-A329-4A93-897E-72B29073DFEDQ34343530-314AD2AD-2C68-43EB-9E33-792BA08B4475Q34409963-2994CACE-36C2-4BD9-B4E5-D13DFD526E43Q34434145-BB3D3136-2EAF-4D36-B3CD-1393B3F89D23Q34496205-D8D7F676-84D8-4183-827A-C1568808C080Q34562333-6540415F-1C6F-4EAD-8BA8-69F93330F1C1Q34579700-EE7A8F05-1918-4890-A39C-08E071A6D461Q34597617-01C9EF01-0B1B-4F14-9677-1147B130DF13Q34650827-DEF3B076-75F1-44D4-A5AE-8F97200E82E1Q34953705-937CEC7B-E7CD-4144-9ECA-99D827742C44Q35031900-5D1B6326-94E8-4CE7-A475-6CB112316419Q35038627-397AA6BD-9AA4-4E74-9C88-17CB892ABA33Q35092092-84E47F71-54E0-42AB-AC17-6B9C094FE4B4Q35140545-86F1D56E-D52E-479D-A87F-E389F8CED305Q35770484-1CB9D131-F2BB-410E-AD75-8E469772BA47Q35834952-E5834681-39C0-415E-8CBC-F4F10E747D80Q35844920-5DBE3A3F-703E-4248-80A4-7971834CD158
P2860
Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Artemisinin resistance in Camb ...... ing problem in Southeast Asia.
@en
type
label
Artemisinin resistance in Camb ...... ing problem in Southeast Asia.
@en
prefLabel
Artemisinin resistance in Camb ...... ing problem in Southeast Asia.
@en
P2093
P356
P1476
Artemisinin resistance in Camb ...... ing problem in Southeast Asia.
@en
P2093
Bryan Smith
Delia Bethell
Duong Socheat
Harald Noedl
Kurt Schaecher
Lon Chan Thap
Mark M Fukuda
Paktiya Teja-Isavadharm
Sabaithip Sriwichai
Sittidech Surasri
P356
10.1086/657120
P407
P577
2010-10-28T00:00:00Z